Somnath Mukherjee, MD, of Oxford University, discusses this phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine- or paclitaxel/carboplatin-based chemoradiation as a pre-operative regimen for resectable esophageal cancer.. (Abstract 3).
Daniel G. Haller, MD, of the Abramson Cancer Center, discusses emerging global approaches to these diseases, emphasizing the studies that allow physicians to individualize treatments.
Jonathan R. Strosberg, MD, of H. Lee Moffitt Cancer Center and Research Institute, discusses progression-free survival, radiographic response, and preliminary overall survival findings of this phase III study on midgut neuroendocrine tumors treated with lutetium Lu-177 dotatate (Abstract 194).
Yoon-Koo Kang, MD, PhD, of the Asan Medical Center, discusses findings from this multicenter, phase II/III study of ado-trastuzumab emtansine vs a taxane in patients with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (Abstract 5).
James L. Abbruzzese, MD, of Duke University, discusses the international outlook on patterns of care and their impact on outcomes.
Toshihiko Doi, MD, PhD, of Japan’s National Cancer Center Hospital East, discusses updated results on pembrolizumab for advanced esophageal cancer (Abstract 7).
